Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Incyte Corporation
Alliance for Clinical Trials in Oncology
University of Leeds
Memorial Sloan Kettering Cancer Center
Massachusetts General Hospital
Xencor, Inc.
Incyte Corporation
AbbVie
AbbVie
Incyte Corporation
Incyte Corporation
Jonsson Comprehensive Cancer Center
Abramson Cancer Center at Penn Medicine
National Institutes of Health Clinical Center (CC)
Swiss Cancer Institute
Novartis
National Cancer Institute (NCI)
INSYS Therapeutics Inc
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)